Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India.
| Revenue (TTM) | $335.93B |
| Gross Profit (TTM) | $177.26B |
| EBITDA | $68.15B |
| Operating Margin | 1.54% |
| Return on Equity | 11.80% |
| Return on Assets | 5.74% |
| Revenue/Share (TTM) | $67.39 |
| Book Value | $0.80 |
| Price-to-Book | 3.00 |
| Price-to-Sales (TTM) | 0.04 |
| EV/Revenue | 3.306 |
| EV/EBITDA | 14.03 |
| Quarterly Earnings Growth (YoY) | -86.20% |
| Quarterly Revenue Growth (YoY) | -11.60% |
| Shares Outstanding | $832.71M |
| Float | $3.59B |
| % Insiders | 0.00% |
| % Institutions | 15.29% |
Volatility is currently expanding
Dr. Reddy's Laboratories NYSE: RDY reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter.
RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.
Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript
Indian drugmaker Dr Reddy's reported an 86% slump in quarterly profit on Tuesday, hurt by pricing pressure and increasing competition in its key U.S. market.
Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Amphastar Pharmaceuticals (AMPH) and Doctor Reddy's (RDY). But which of these two companies is the best option for those looking for undervalued stocks?
The country is the first in the G7 forum to approve a generic version of the massively popular GLP-1 diabetes treatment.
HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection.
